Congress targets rare disease research gap in minority communities

What it does

The HEARD Act expands federal research, training, and data collection on rare diseases disproportionately affecting minority populations. It directs the NIH to coordinate research efforts, establishes physician and health professional training programs, funds data collection and awareness campaigns, and creates loan repayment and scholarship programs to recruit health professionals to serve these populations. The bill also requires the FDA and Medicare to review barriers to access and clinical trial diversity.

Why we flagged it

The bill's core mechanism is expanding federal research capacity and training infrastructure focused on rare diseases in minority populations. It is a public health investment bill, not a regulatory change or market intervention.

What the text implies

• Loan repayment program (up to $50K/year per provider) may create long-term federal budget obligations if uptake is high, though amounts are capped and subject to appropriations.
• Requirement for FDA survey on clinical trial diversity and recommendations may lead to future regulatory changes affecting drug development timelines or trial design requirements.
• Medicare review of barriers to rare disease treatment for beneficiaries of color could expose systemic access gaps, potentially triggering coverage or reimbursement policy changes.
• Tribal epidemiology center grants expand federal health infrastructure in Native American communities, creating new data collection and research capacity that may inform future policy.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill increases federal research funding and training capacity focused on rare diseases affecting minority populations, addressing documented health disparities and expanding access to specialized care. Citizens in affected communities gain from improved research, better-trained providers, and increased awareness; the loan repayment and scholarship programs create incentives for providers to serve underserved populations.

Who stands to gain

• medical schools and nursing programs (grant recipients)
• health professional training institutions
• Tribal Epidemiology Centers and Tribal/Urban Indian Health Centers
• nonprofit research entities and advocacy groups (data collection grants)
• physicians and genetic counselors (loan repayment and scholarship beneficiaries)

Named in the bill

National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health Resources and Services Administration (HRSA), Indian Health Service, Medicare, Tribal Epidemiology Centers, accredited schools of medicine and nursing

Where it stands

5 cosponsors: 5 Democrats.

• Feb 27, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 27, 2025 — Referred to House Committee on Natural Resources and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $20,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Marilyn Strickland, the sponsor, reported $767,699 in PAC receipts in the 2026 cycle.

• Black Women's Health Imperative — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jan 9, 2026. A filing shows who paid to lobby on a bill it names, not what changed.